cardiac disease. Atherosclerotic heart disease
Conditions
Interventions
Intervention 1: Intervention group: injected 500cc intravenous lipid (construction company Frezenius) emulsion 20% injected during the 3 hours at 1cc/kg/h. Intervention 2: Control group: Patients rece
Treatment - Drugs
Placebo
Intervention group: injected 500cc intravenous lipid (construction company Frezenius) emulsion 20% injected during the 3 hours at 1cc/kg/h.
Control group: Patients received 500 cc normal saline during the 3-hours at 1cc /kg /h
Sponsors
Vice Chancellor for Research, Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: Candidate for CABG surgery; consent to participate in research; The first surgery of CABG; EF above 35 ; BMI less than 30 ; lack of familial metabolic disorder; no need for mechanical ventilation and inotrope Exclusion criteria: re-heart surgery; need to balloon pump; rate disorder during surgery and then
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ejection Fraction. Timepoint: Before and after surgery. Method of measurement: Echocardiography device. | — |
Secondary
| Measure | Time frame |
|---|---|
| Stay in intensive care units. Timepoint: Since admission to the ICU after surgery until discharge or transfer to the. Method of measurement: Observation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Majid Razavi
Mashhad University of Medical Sciences
Outcome results
None listed